The availability of our team to support you has not changed as a result of COVID-19. If there is a way we can assist you, we are here to help - Contact us

Horizon Discovery & Cancer Research UK form Drug Discovery Venture

28 May 2008

Cell Based Assay NewsCell Based Assay NewsHorizon Discovery (Horizon) today announced it will be a founding member of VIMCAD, a consortium of leading UK Oncology research groups comprising: Cancer Research UK’s Cambridge Research Institute; Horizon Discovery in Cambridge; St George’s University of London; University of Glasgow and the University of Liverpool.

VIMCAD will apply leading-edge in vitro cellular modeling and imaging techniques to translate molecular and cell-based observations on cellular senescence into a viable drug discovery strategy.

The key objectives of the VIMCAD research program are: the identification critical paths for cellular senescence with a focus on human melanoma; development of genetically defined ‘isogenic’ human tumour cell-lines with matched normal gentetic backgrounds to rationally screen for novel compounds that modulate senescence and; the identification of small molecules and miRNA target leads for drug development and pathway manipulation.

VIMCAD is being funded by Cancer Research UK for an initial period of 24 months and will be the repository for valuable new intellectual property. Following this period an industrial partner will be sought by Cancer Research UK to develop the new intellectual property.

Horizon will contribute a valuable component of the research program, namely the development of genetically defined (by target patient genotype) human isogenic cancer cell-lines that can be used to find new drug candidates in high-content screens.
In return for its involvement Horizon will receive a six-figure fee and retain ownership of the developed isogenic cell-lines, which will allow the dissemination of these unique tools to its academic, biotech and pharmaceutical customers. Horizon will also be an equal shareholder in VIMCAD and the intellectual property contained within it.